{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:06:14Z","timestamp":1784009174834,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>To evaluate the safety profile of Yisheng Jun\u2019an\u00ae freeze-dried human rabies vaccine (Vero cell) through post-marketing surveillance in China (2020\u20132024), focusing on adverse reaction patterns and influencing factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study analyzed 2,419 adverse events from the national Direct Adverse Event Reporting System (DAERS) and manufacturer-collected data. Adverse reactions were categorized by type, severity, and subgroup (age, gender, dose number, etc.) using the Medical Dictionary for Regulatory Activities (MedDRA) for standardized coding. Analysis of incidence rates with 95% confidence intervals, use of the chi-square test to assess associations, and cross-subgroup comparisons were conducted to elucidate the safety profile of the vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2,419 AEs were reported, yielding an overall incidence of 7.406 per 100,000 doses (95% CI 7.11\u20137.71). Systemic reactions comprised 83.38% and local reactions 16.62%. Seventeen serious adverse events (0.70%) occurred; no deaths were reported and all recovered. The most common categories were general disorders\/administration-site conditions (83.38%) and immune system disorders (5.70%). AEs were most frequent after the first dose (85.49%) and declined markedly with subsequent doses. Systemic reactions were more common in children (0\u201310\u202fyears: 37.99%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Yisheng Jun\u2019an\u00ae rabies vaccine exhibits a favorable safety profile with mild-to-moderate reactions, supporting its use in post-exposure prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1741521","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:40:30Z","timestamp":1784007630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A post-marketing surveillance study of a human rabies vaccine in China (2020\u20132024)"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhijie","family":"Cui","sequence":"first","affiliation":[{"name":"Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfu","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Taikang Yanyuan Rehabilitation Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Ran","sequence":"additional","affiliation":[{"name":"Hu'an Biotechnology (Beijing) Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Hu'an Biotechnology (Beijing) Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Gan","sequence":"additional","affiliation":[{"name":"Hu'an Biotechnology (Beijing) Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rabies, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","article-title":"30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience","volume":"14","author":"Giesen","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2147\/IDR.S314881","article-title":"Epidemiological analysis of rabies in Central China from 2013 to 2018","volume":"14","author":"Cai","year":"2021","journal-title":"Infect Drug Resist"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1474-4422(13)70038-3","article-title":"Human rabies: neuropathogenesis, diagnosis, and management","volume":"12","author":"Hemachudha","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/ccr3.1846","article-title":"Hydrophobia of human rabies","volume":"6","author":"Tongavelona","year":"2018","journal-title":"Clin Case Reports"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4065\/79.5.671","article-title":"Overview, prevention, and treatment of rabies","volume":"79","author":"Hankins","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1186\/s12879-024-09864-2","article-title":"Epidemiological characteristics of human rabies cases reported by sites in China from 2006 to 2022","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0013089","DOI":"10.1371\/journal.pntd.0013089","article-title":"Characteristics, post-exposure prophylaxis usage, and clinical features of Chinese human rabies cases, 2016-2020","volume":"19","author":"Ren","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"100105","DOI":"10.1016\/j.vetvac.2025.100105","article-title":"Rabies vaccines: journey from classical to modern era","volume":"4","author":"Khan","year":"2025","journal-title":"Veterinary Vaccine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101204","DOI":"10.1016\/j.coviro.2022.101204","article-title":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","volume":"53","author":"de Melo","year":"2022","journal-title":"Curr Opin Virol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: a post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.11675\/j.issn.0253-4304.2014.11.34","article-title":"Analysis of adverse reactions following rabies vaccination with Liaoning Chengda and Liaoning Yisheng vaccines","volume":"36","author":"Luo","year":"2014","journal-title":"Guangxi Med J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.46234\/ccdcw2026.079","article-title":"Post-marketing surveillance data of adverse events following immunization with human rabies vaccine\u2014China, 2021\u20132024","volume":"8","author":"Lina","year":"2026","journal-title":"China CDC Weekly"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.46234\/ccdcw2025.210","article-title":"Active surveillance on safety and compliance of freeze-dried human rabies vaccine (Vero cell)\u2014Jiangsu Province, China, 2023\u20132024","volume":"7","author":"Yanjun","year":"2025","journal-title":"China CDC Weekly."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0004846","DOI":"10.1371\/journal.pntd.0004846","article-title":"Post-marketing surveillance of human rabies diploid cell vaccine (Imovax) in the vaccine adverse event reporting system (VAERS) in the United States, 1990\u20132015","volume":"10","author":"Moro","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1080\/21645515.2017.1279770","article-title":"Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects","volume":"13","author":"Shi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1152899","DOI":"10.3389\/fimmu.2023.1152899","article-title":"Immunogenicity and reactogenicity of Inactivated SARS-CoV-2 vaccines in healthy adults","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12879-022-07175-y","article-title":"Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study","volume":"22","author":"Urakawa","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13293-024-00625-z","article-title":"Sex and gender differences in adverse events following influenza and COVID-19 vaccination","volume":"15","author":"Yin","year":"2024","journal-title":"Biol Sex Differ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/jech-2023-220781","article-title":"Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials","volume":"77","author":"Kiely","year":"2023","journal-title":"J Epidemiol Community Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjebm-2020-111507","article-title":"Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?","volume":"27","author":"Dhanda","year":"2022","journal-title":"BMJ Evid Based Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2211896","DOI":"10.1080\/21645515.2023.2211896","article-title":"Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10\u201350 years old: randomized, blinded, parallel controlled phase III clinical study","volume":"19","author":"Huang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1016\/j.vaccine.2011.01.053","article-title":"Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.18502\/ijph.v51i5.9412","article-title":"Post-exposure prophylactic vaccination against rabies: a systematic review","volume":"51","author":"Ahmad","year":"2022","journal-title":"Iran J Public Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7774\/cevr.2025.14.e1","article-title":"A prospective study on safety and clinical efficacy of rabies biologicals in paediatric patients with category III animal exposure","volume":"14","author":"Fotedar","year":"2025","journal-title":"Clin Exp Vaccine Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100365","DOI":"10.1016\/j.jve.2024.100365","article-title":"Study on immune persistence of the CTN-1V strain rabies vaccine in humans","volume":"10","author":"Wang","year":"2024","journal-title":"J Virus Erad"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2138049","DOI":"10.1080\/21645515.2022.2138049","article-title":"A simulated, randomized study on the safety and immunogenicity of three consecutive commercial-scale batches of the CTN-1V strain human rabies vaccine to verify the inter-batch consistency","volume":"18","author":"Zhou","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.lansea.2023.100207","article-title":"Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure","volume":"14","author":"Kang","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/ph17060807","article-title":"Pharmacovigilance in vaccines: importance, main aspects, perspectives, and challenges-a narrative review","volume":"17","author":"Hodel","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12889-025-21805-5","article-title":"Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study","volume":"25","author":"Soltani","year":"2025","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1741521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:40:34Z","timestamp":1784007634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1741521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2026.1741521"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1741521","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1741521"}}